Bavarian Nordic Completes Share Buy-Back Program Transactions
News related to:Bavarian Nordic A/S · 1 min read
COPENHAGEN, Denmark, September 14, 2026 /CourierPR/ -- Bavarian Nordic, a global vaccine company, has announced the completion of transactions under its share buy-back program. The program, launched on September 1, 2026, aims to repurchase shares up to a value of DKK 250 million over the period from September 1, 2026, to October 30, 2026. The company is executing the program in accordance with the Safe Harbour Regulation, which includes Regulation (EU) No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
Since the last announcement on September 7, 2026, Nordea has acted on behalf of Bavarian Nordic to repurchase shares. The transactions are detailed on the company’s website at bavarian-nordic.com. As of the latest transactions, Bavarian Nordic now holds a total of 3,842,026 treasury shares, representing 4.85% of the company’s share capital.
Bavarian Nordic, headquartered in Denmark, is known for its mission to improve health and save lives through innovative vaccines. The company has a leading portfolio of travel vaccines and is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness.
The share buy-back program is part of Bavarian Nordic’s ongoing efforts to optimize its capital structure and return value to shareholders. The company continues to monitor market conditions and will adjust its share repurchase activities as necessary to align with its strategic objectives.
The transactions under the share buy-back program are executed in a manner that complies with regulatory requirements, ensuring transparency and fairness in the company’s capital management practices. Bavarian Nordic remains committed to maintaining strong financial discipline and delivering value to its shareholders.